DiaMedica Therapeutics (DMAC) Retained Earnings (2017 - 2026)

DiaMedica Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$182.8 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 200.63% year-over-year to -$182.8 million in Q1 2026; TTM through Mar 2026 was -$182.8 million, a 200.63% decrease from a year earlier, with the FY2025 full-year figure at -$172.8 million, down 195.61% from the prior year.
• Retained Earnings fell to -$182.8 million in Q1 2026 per DMAC's latest filing, from -$172.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $215.6 million in Q3 2025 and bottomed at -$182.8 million in Q1 2026.
• The 5-year median for Retained Earnings is -$89.4 million (2022), against an average of -$5.9 million.
• Across the five-year window, Retained Earnings plunged 2978800.0% in 2022 and soared 264.79% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $128.1 million in 2022, then plunged by 190.22% to -$115.6 million in 2023, then jumped by 256.37% to $180.7 million in 2024, then slumped by 195.61% to -$172.8 million in 2025, then decreased by 5.81% to -$182.8 million in 2026.
• Per Business Quant, the three latest DMAC Retained Earnings figures stand at -$182.8 million (Q1 2026), -$172.8 million (Q4 2025), and $215.6 million (Q3 2025).